1상모집 중

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia

연구 개요

The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. Once the researchers find this dose, it will test it in a new group of participants to see if it is effective in treating their relapsed/refractory AML.

스폰서
협력: 다케다
적응증
Acute Myeloid Leukemia
중재
ADCLEC.syn1 CAR T cells, Conditioning chemotherapy
목표 등록
40
시작일
2024-04-18
완료(예정)
2028-04-18

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia (NCT05748197) | BioPulse